<DOC>
	<DOCNO>NCT00328939</DOCNO>
	<brief_summary>This local registration study China compare safety efficacy ARIXTRA Enoxaparine patient undergo elective major hip knee replacement revision component .</brief_summary>
	<brief_title>ARIXTRA Local Study For Registration In China .</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Inclusion criterion : Patients undergo either elective major hip knee replacement revision . Signed write informed consent . Men woman nonchild bear potential ( i.e. , post menopausal hysterectomy bilateral tubule ligation ) woman childbearing potential without plan child . Exclusion criterion : History serious active bleeding last 3 month Concurrent history thrombocytopenia ( Platelet &lt; 100x109/L ) History hypersensitivity reaction heparin , Low molecular weight heparin pork product Acute bacterial endocarditis Congenital acquire bleed disease last 3 month Concurrent uncontrolled ulcer gastrointestinal disease blood vessel dysplasia Concurrent hemorrhagic cerebrovascular disease surgical history cerebral , spine eye Conditions need leave tubule intradural extradural Contraindication anticoagulant condition require take long term oral anticoagulant Abnormality hepatic ( &gt; 1.5x UNL ) , renal ( Clcr &lt; 30ml/min ) cardiac function , uncontrolled hypertension tumor Concurrent disorder blood vessel lower limb Positive result Human Chorionic Gonadotropin test Participated investigational study Deep Vein Thrombosis prevention last 90 day . Concurrently hip knee double hip/knee replacement time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>ARIXTRA</keyword>
	<keyword>prevention DVT</keyword>
</DOC>